Tisha San Miguel

发表

Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quino

J. McCarter, D. Whittington, Iain D. G. Campuzano, 2016, Journal of medicinal chemistry.

Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability.

Daniel J. Freeman, J. McCarter, Nancy Zhang, 2011, Journal of medicinal chemistry.

Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.

Daniel J. Freeman, R. Wahl, J. McCarter, 2011, Journal of medicinal chemistry.

Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.

Xiaolin Hao, Ben Fisher, Andreas Reichelt, 2015, Journal of medicinal chemistry.

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

J. Desai, R. Govindan, W. Ouyang, 2019, Nature.

Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors.

N. Chen, J. McCarter, K. Rex, 2019, Journal of medicinal chemistry.

Phosphoinositide-3-kinase inhibitors: evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511.

J. McCarter, D. Whittington, A. Tasker, 2014, Bioorganic & medicinal chemistry letters.

Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C.

R. Fucini, Andrew M. Sawayama, J. McCarter, 2019, ACS medicinal chemistry letters.

A telomerase enzymatic assay that does not use polymerase chain reaction, radioactivity, or electrophoresis.

R. Wahl, M. Robinson, K. Kearns, 2004, Analytical biochemistry.

Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid.

Yuan Cheng, Wenge Zhong, Michael D Bartberger, 2012, Journal of medicinal chemistry.

The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors.

J. McCarter, D. Whittington, Nancy Zhang, 2015, Bioorganic & medicinal chemistry letters.

Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors.

J. McCarter, D. Whittington, D. Metz, 2016, Journal of medicinal chemistry.

Synthesis and SAR study of potent and selective PI3Kδ inhibitors.

J. McCarter, D. Metz, S. Wong, 2015, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.

R. Wahl, S. Hitchcock, Yuan Cheng, 2012, Journal of medicinal chemistry.

Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.

Daniel J. Freeman, Hongyu Liao, Nancy Zhang, 2011, Journal of medicinal chemistry.

The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.

T. Bush, M. Rong, K. Sham, 2013, Bioorganic & medicinal chemistry letters.

High-Throughput Mass Spectrometric Analysis of Covalent Protein-Inhibitor Adducts for the Discovery of Irreversible Inhibitors

Iain D G Campuzano, J. McCarter, T. Arvedson, 2016, Journal of biomolecular screening.

Facile Modulation of Antibody Fucosylation with Small Molecule Fucostatin Inhibitors and Cocrystal Structure with GDP-Mannose 4,6-Dehydratase.

J. B. Jordan, J. McCarter, M. Mujacic, 2016, ACS chemical biology.